93
Participants
Start Date
November 30, 2022
Primary Completion Date
December 1, 2024
Study Completion Date
December 1, 2025
PD-1 antibody
PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
Capecitabine
Capecitabine: 1000mg/m2 d1-14 q3w
5FU
400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
folinic acid
400 mg/m2 q2w
Oxaliplatin
130 mg/m² q3w or 85 mg/m² q2w
Irinotecan
180 mg/m² q2w and 200 mg/m² q3w
Raltitrexed
2 mg/m² q2w and 3 mg/m² q3w
Cetuximab
400 mg/m² q2w
Bevacizumab
5 mg/kg q2w or 7.5mg/kg q3w
Radiation
"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER